iDenfy’s revamped AML Screening software now includes new risk categories, better PEP status labeling, and other built-in AML features The new iDenfy's AML Screening software redefines how companies ...
A total of 1482 adult AML patients were screened for DNMT3A mutations. One hundred and seventy-one adult AML patients (aged 18–87 years) were found to be DNMT3A mutated and had available diagnostic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback